Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 17/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617066 | 0.87 | NOS2 (0.43) | NOS2 | |
| SCHEMBL5189932 | 0.85 | NOS2 (0.53) | NOS2 | |
| SCHEMBL7062077 | 0.84 | NOS2 (0.41) | NOS2TP53GLACYP3A4CYP2D6 | |
| SCHEMBL5192244 | 0.80 | KDM4E (0.39) | NOS2TP53GLACYP3A4CYP2D6 | |
| SCHEMBL6328458 | 0.79 | NOS2 (0.49) | NOS2 | |
| SCHEMBL5194260 | 0.76 | NOS2 (0.71) | NOS2 | |
| SCHEMBL5191433 | 0.76 | NOS2 (0.67) | NOS2 | |
| SCHEMBL5192789 | 0.75 | NOS2 (0.55) | NOS2 | |
| SCHEMBL6324810 | 0.75 | NOS2 (0.52) | NOS2 | |
| SCHEMBL5193352 | 0.75 | NOS2 (0.58) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-17 | — | — | US | claimed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885TP53 4248/4885GLA 1777/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885TP53 4248/4885GLA 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.